All articles tagged with #excessive daytime sleepiness
Scientists have identified key molecules linked to metabolism that may influence excessive daytime sleepiness (EDS), with dietary factors such as omega-3 fatty acids reducing risk and foods high in tyramine increasing it. These findings suggest lifestyle and dietary modifications could help manage EDS, which affects about one in five people, and highlight the role of genetics and metabolism in sleep health.
Scientists have identified key molecules linked to metabolism that may cause excessive daytime sleepiness (EDS), and suggest that dietary modifications, such as increasing omega-3 and omega-6 fatty acids and reducing tyramine-rich foods, could help manage the condition, which affects about one in five people.
Researchers have identified a drug called solriamfetol that shows promise in relieving excessive daytime sleepiness (EDS) in individuals with obstructive sleep apnea (OSA). In a study reviewing 14 clinical trials, solriamfetol was found to be more effective than placebos in combating EDS. Two other anti-fatigue medications, armodafinil-modafinil and pitolisant, also showed some effectiveness. However, solriamfetol had the largest statistical difference in terms of wakefulness. The drugs' potential benefits and side effects, particularly in the long term, require further investigation. These medications may also be useful in treating related conditions such as chronic fatigue syndrome and long COVID. With the high prevalence of OSA globally, better treatments are urgently needed.
A study conducted by researchers from McMaster University has found that solriamfetol is the most effective treatment for excessive daytime sleepiness (EDS) in individuals with obstructive sleep apnea (OSA), in addition to the standard positive airway pressure (PAP) mask treatment. The study, based on a comprehensive review of 14 clinical trials, suggests that solriamfetol, along with armodafinil-modafinil and pitolisant, can combat fatigue effectively. However, solriamfetol may raise blood pressure, which is a concern for OSA patients with cardiovascular issues. The researchers believe that these anti-fatigue medications could also be beneficial for related conditions such as chronic fatigue syndrome and long COVID.